Identification of ING 4 ( Inhibitor of Growth 4 ) as a Modulator of Docetaxel Sensitivity in Human Lung Adenocarcinoma

Rui Wang,Jiayuan Huang,Bing Feng,Wei De,Longbang Chen

2012-01-01

Abstract:INTRODUCTION Non–small cell lung cancer (NSCLC) has been one of the most lethal malignancies around the world. Adenocarcinoma of the lung is the most common type of lung cancer and accounts for 30% to 35% of primary lung tumors (1). Currently, systemic chemotherapy is still an important treatment option for patients with advanced lung adenocarcinoma (2). Docetaxel (DTX) has become an integral part of several commonly used chemotherapy regimens in NSCLC (3). However, the development of intrinsic or acquired resistance to DTX remains the greatest obstacle to the successful treatment of patients with lung adenocarcinoma. Thus, elucidating the mechanisms by which DTX resistance arises in lung adenocarcinoma remains a critical issue for overcoming and predicting DTX resistance in NSCLC. Recently, a wealth of novel insights into molecular targets and mechanisms of cancer chemosensitivity and resistance have yielded much progress in genomic and proteomic studies (4). DTX (Taxotere) is a novel microtubule-stabilizing agent that has been synthesized from a precursor extracted from a renewable natural source, the needles of the European yew, Taxus baccata (5). This agent can enhance microtubule assembly and inhibit the depolymerization of tubulin. In the clinical setting, DTX has been used for adjuvant therapy after resection of localized NSCLC and in combination with radiation for locally advanced NSCLC and treatment of patients with advanced NSCLC (6,7). However, the therapeutic results in some patients with advanced NSCLC have been unsatisfying, as in cases of intrinsic or acquired chemoresistance. The dysregulation of oncogenes such as Bcl-2 family members or tumor suppressors such as PUMA (p53 upregulated modulator of apoptosis) has been found to be associated with DTX resistance of tumor cells (8–10). However, the molecular mechanisms of DTX resistance are very complicated and require further elucidation. Previously, we successfully established a DTX-resistant lung adenocarcinoma cell line (SPC-A1/DTX) from a DTXnonresistant lung adenocarcinoma cell Identification of ING4 (Inhibitor of Growth 4) as a Modulator of Docetaxel Sensitivity in Human Lung Adenocarcinoma